tradingkey.logo

Harrow Inc

HROW

38.970USD

+0.180+0.46%
取引時間 ET15分遅れの株価
1.43B時価総額
損失額直近12ヶ月PER

Harrow Inc

38.970

+0.180+0.46%
詳細情報 Harrow Inc 企業名
Harrow, Inc. is an eyecare pharmaceutical company. The Company is engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the United States market. It provides a comprehensive portfolio of prescription and non-prescription pharmaceutical products. It owns commercial rights to portfolios of branded ophthalmic pharmaceutical products in North America, all of which are marketed under the Harrow name. It owns and operates ImprimisRx, an ophthalmology-focused pharmaceutical-compounding business. It owns United States commercial rights to various products: IHEEZO, VEVYE, TRIESENCE, VIGAMOX, ILEVRO, FLAREX, NATACYN, ZERVIATE and others. VIGAMOX (moxifloxacin hydrochloride ophthalmic solution) 0.5%, a fluoroquinolone antibiotic eye drops for the treatment of bacterial conjunctivitis caused by susceptible strains of organisms. IHEEZO (chloroprocaine hydrochloride ophthalmic gel) 3% is a low-viscosity gel indicated for ocular surface anesthesia.
企業情報
企業コードHROW
会社名Harrow Inc
上場日Feb 08, 2013
最高経営責任者「CEO」Mr. John P. Saharek
従業員数382
証券種類Ordinary Share
決算期末Feb 08
本社所在地1A Burton Hills Blvd
都市NASHVILLE
証券取引所NASDAQ Global Market Consolidated
United States of America
郵便番号37215
電話番号16157334731
ウェブサイトhttps://www.harrow.com/
企業コードHROW
上場日Feb 08, 2013
最高経営責任者「CEO」Mr. John P. Saharek
役員一覧
会社名
会社名/ポジション
ポジション
株式保有
変動額
Mr. Mark L. Baum, J.D.
Mr. Mark L. Baum, J.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
2.89M
+11.03%
Mr. Andrew R. Boll
Mr. Andrew R. Boll
President, Chief Financial Officer, Company Secretary
President, Chief Financial Officer, Company Secretary
777.84K
+36.92%
Mr. John P. Saharek
Mr. John P. Saharek
President and Chief Executive Officer of ImprimisRx
President and Chief Executive Officer of ImprimisRx
467.39K
+58.62%
Dr. Adrienne L. Graves, Ph.D.
Dr. Adrienne L. Graves, Ph.D.
Independent Director
Independent Director
--
--
Mrs. Lauren P. Silvernail
Mrs. Lauren P. Silvernail
Independent Director
Independent Director
--
--
Mr. Perry J. Sternberg
Mr. Perry J. Sternberg
Lead Independent Director
Lead Independent Director
--
--
Mr. Amir Shojaei, Ph.D.
Mr. Amir Shojaei, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
会社名
会社名/ポジション
ポジション
株式保有
変動額
Mr. Mark L. Baum, J.D.
Mr. Mark L. Baum, J.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
2.89M
+11.03%
Mr. Andrew R. Boll
Mr. Andrew R. Boll
President, Chief Financial Officer, Company Secretary
President, Chief Financial Officer, Company Secretary
777.84K
+36.92%
Mr. John P. Saharek
Mr. John P. Saharek
President and Chief Executive Officer of ImprimisRx
President and Chief Executive Officer of ImprimisRx
467.39K
+58.62%
Dr. Adrienne L. Graves, Ph.D.
Dr. Adrienne L. Graves, Ph.D.
Independent Director
Independent Director
--
--
Mrs. Lauren P. Silvernail
Mrs. Lauren P. Silvernail
Independent Director
Independent Director
--
--
Mr. Perry J. Sternberg
Mr. Perry J. Sternberg
Lead Independent Director
Lead Independent Director
--
--
収益内訳
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
事業別USD
会社名
収益
比率
Product Sales Net
47.74M
0.00%
Transfer of acquired product sales/profit
86.00K
0.00%
データなし
事業別
地域別
事業別USD
会社名
収益
比率
Product Sales Net
47.74M
0.00%
Transfer of acquired product sales/profit
86.00K
0.00%
株主
更新時刻: Sat, Aug 16
更新時刻: Sat, Aug 16
株主統計
種類
株主統計
株主統計
比率
Opaleye Management Inc.
10.55%
Baum (Mark L)
7.80%
BlackRock Institutional Trust Company, N.A.
6.09%
Private Capital Management
5.26%
The Vanguard Group, Inc.
5.03%
他の
65.27%
株主統計
株主統計
比率
Opaleye Management Inc.
10.55%
Baum (Mark L)
7.80%
BlackRock Institutional Trust Company, N.A.
6.09%
Private Capital Management
5.26%
The Vanguard Group, Inc.
5.03%
他の
65.27%
種類
株主統計
比率
Investment Advisor/Hedge Fund
18.79%
Investment Advisor
18.12%
Hedge Fund
17.30%
Individual Investor
15.72%
Research Firm
2.46%
Bank and Trust
0.35%
Pension Fund
0.29%
Sovereign Wealth Fund
0.07%
Insurance Company
0.03%
他の
26.87%
機関投資家保有株
更新時刻: Tue, Jul 1
更新時刻: Tue, Jul 1
報告期間
機関投資家数
保有株式数
比率
変動額
2025Q2
345
26.63M
72.57%
-2.99M
2025Q1
354
25.78M
70.87%
-4.22M
2024Q4
350
26.13M
73.38%
-4.49M
2024Q3
325
25.90M
72.95%
-2.80M
2024Q2
296
24.70M
70.19%
-6.36M
2024Q1
284
26.34M
74.95%
-7.20M
2023Q4
279
28.26M
80.94%
-4.94M
2023Q3
275
28.51M
81.73%
-152.59K
2023Q2
265
25.64M
85.30%
+312.85K
2023Q1
246
23.86M
79.81%
+1.57M
詳細を見る
株主動向
会社名
保有株式数
比率
変動額
変動率
日付
Opaleye Management Inc.
3.94M
10.72%
-4.80K
-0.12%
Jun 04, 2025
Baum (Mark L)
2.60M
7.08%
+461.94K
+21.61%
Apr 21, 2025
BlackRock Institutional Trust Company, N.A.
2.27M
6.2%
-1.07K
-0.05%
Mar 31, 2025
Private Capital Management
1.89M
5.15%
+195.64K
+11.54%
Mar 31, 2025
The Vanguard Group, Inc.
1.86M
5.07%
-6.65K
-0.36%
Mar 31, 2025
Kaufman (Daniel)
1.68M
4.59%
-222.91K
-11.69%
Aug 12, 2024
Braidwell LP
956.84K
2.61%
+49.80K
+5.49%
Mar 31, 2025
Geode Capital Management, L.L.C.
774.08K
2.11%
+52.97K
+7.35%
Mar 31, 2025
Boll (Andrew R)
777.84K
2.12%
+209.75K
+36.92%
Apr 21, 2025
State Street Global Advisors (US)
786.48K
2.14%
-41.22K
-4.98%
Mar 31, 2025
詳細を見る
関連ETF
更新時刻: Wed, Aug 6
更新時刻: Wed, Aug 6
銘柄名
比率
SPDR S&P Pharmaceuticals ETF
1.81%
Invesco Dorsey Wright Healthcare Momentum ETF
1.59%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
1.12%
iShares U.S. Pharmaceuticals ETF
0.49%
First Trust Small Cap Growth AlphaDEX Fund
0.37%
Invesco Dorsey Wright SmallCap Momentum ETF
0.36%
iShares Micro-Cap ETF
0.22%
ProShares Ultra Nasdaq Biotechnology
0.12%
Invesco Nasdaq Biotechnology ETF
0.11%
Fidelity Small-Mid Multifactor ETF
0.1%
詳細を見る
SPDR S&P Pharmaceuticals ETF
比率1.81%
Invesco Dorsey Wright Healthcare Momentum ETF
比率1.59%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
比率1.12%
iShares U.S. Pharmaceuticals ETF
比率0.49%
First Trust Small Cap Growth AlphaDEX Fund
比率0.37%
Invesco Dorsey Wright SmallCap Momentum ETF
比率0.36%
iShares Micro-Cap ETF
比率0.22%
ProShares Ultra Nasdaq Biotechnology
比率0.12%
Invesco Nasdaq Biotechnology ETF
比率0.11%
Fidelity Small-Mid Multifactor ETF
比率0.1%
配当金
過去5年間の配当金総支払額は 0.00 米ドルである。
日付
配当金
権利確定日
支払日
配当落ち日
データなし
株式分割
日付
種類
比率
データなし
日付
種類
比率
データなし
KeyAI